anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Neuromonitoring of patients with severe neurological illness are detailed elsewhere. In the setting of cerebral edema, ICP monitoring is a staple of neurocritical care. Pressure AR is an important hemodynamic mechanism that protects the brain against inappropriate fluctuations in CBF in the face of changing CPP. Both static and dynamic AR have been monitored in neurocritical care to aid prognostication and contribute to individualizing optimal CPP targets in patients. Theoretically, failure of cerebral AR is associated with poor outcomes in various acute neurological diseases. Continuous bedside monitoring of autoregulation is now feasible and should be considered as a part of multimodality monitoring including measurement of pressure reactivity. A previous study documented that REG (REGx) and ICP (PRx) has high correlation in order to detect the lower limit of CBF AR. The fundamental relationships between SAP, vessel tone, cerebral blood volume and ICP form the basis for the pressure reactivity index (PRx). PRx is analogous to other time domain AR indices and is calculated as the continuous correlation between thirty consecutive time-averaged (10 s) SAP and ICP values. A positive index (positive correlation) implies impaired passive CBF AR, while a negative index (inverse correlation) implies intact, active AR. The utility and feasibility of REG as a monitoring modality is previously demonstrated and validated as a reflection of cerebrovascular reactivity. The bioimpedance amplifier was used previously at Walter Reed Army Institute of Research (WRAIR) and Naval Medical Research Center (Silver Spring, MD); and has an FDA safety clearance. It is expected that REG can predict evolving vasospasm and expanding intracranial bleeding amongst several other clinical applications.
BACKGROUND: Simultaneous bilateral total hip arthroplasty (SI-THA) results in more blood loss and a greater need for postoperative allogeneic blood transfusion (ABT). Previous studies have reported that multimodal patient blood management (PBM) strategies were associated with a smaller effect of intraoperative cell salvage (ICS) in unilateral total hip arthroplasty. However, there are few studies on the role of ICS in SI-THA. This study aims to explore the effect of ICS with multimodal PBM strategies on SI-THA and to identify risk factors associated with ABT.
METHODS: This retrospective matched cohort study included 72 patients in the ICS group and 72 patients in the control group who were matched according to age, sex, and year of hospitalization. Demographic data, hematological indicators, blood loss, and ABT were compared between the two groups. Logistic regression analysis was performed to identify independent risk factors for postoperative ABT. Postoperative outcomes were also recorded.
RESULTS: In the cohort of 144 patients, 27 patients (37.5%) in the ICS group while 45 patients (62.5%) in the control group received postoperative ABT after SI-THA. Compared with the control group, the ICS group showed significant differences in terms of blood loss, postoperative hemoglobin and hematocrit. The transfused volume of allogeneic red blood cells per ABT patient was also lower in the ICS group. Multivariate logistic regression analysis indicated that sex, the utilization of ICS, and preoperative hematocrit level were identified as independent factors associated with postoperative ABT. The utilization of ICS significantly shortened off-bed time and length of hospital stay, but had no effect on early pain and functional outcomes.
CONCLUSION: The utilization of ICS can significantly affect postoperative ABT in SI-THA patients with multimodal PBM strategies. Sex, the utilization of ICS and preoperative hematocrit level were identified as independent factors associated with postoperative ABT. The utilization of ICS promoted weight-bearing functional exercises, but had no effect on early outcomes.
All patients will receive daily radiation treatment with intensity-modulated radiotherapy (IMRT) - PTV56 and PTV50.4. Treatment will be given 5 days per week and will not routinely be delivered on Saturday, Sunday or major holidays unless a treatment is missed during the week due to technical and/or medical reasons. No more than 5 treatments should be given per week.
OBJECTIVE: Studies in India and other low-income countries find an inconsistent association between mobility/migration and sexually transmitted infections (STIs) among men. This study comprehensively examined the association between mobility and STIs among men in India. It also assessed heterogeneous associations of mobility, alcohol consumption, and risky sexual behavior with STIs using interaction analysis.
METHODS: We utilized a sample of 71,128 sexually active men aged 15-54 years from the 2019-21 National Family Health Survey-5. Binary logistic regression models were employed to study the associations.
RESULTS: Among the study participants, 16% were mobile and away from home for a month or more in the last 12 months. Around 29% of men reported alcohol consumption and 6% had risky sexual behavior (sexual intercourse with a non-marital/non-cohabitating partner). Regression results suggest that mobility (AOR: 1.41, 95% CI: 1.29-1.55 [short-duration]; AOR: 1.95, 95% CI: 1.77-2.13 [long-duration]) and alcohol consumption (AOR: 1.32, 95% CI: 1.24-1.40) were significantly associated with an increased risk of STIs, even after controlling for socio-demographic covariates. Interaction analysis further reveals that mobile men who consumed alcohol and engaged in risky sexual behavior had a significantly higher likelihood of contracting an STI-twice as high in cases of short-duration mobility and three times higher in cases of long-duration mobility.
CONCLUSION: Our study indicates that both short and long-duration mobility are significantly associated with an increased risk of STIs among men. Alcohol consumption and risky sexual behavior further exacerbate the risk of STIs in mobile men. Initiatives for STI/HIV prevention among men must pay particular attention to temporary mobile men for both short and long durations.
All volunteers be subjected to 16 - 20 weeks of full body resistance exercise training (2 times per week. However, usual care program.
The present invention relates to a sustained release composition for the targeted delivery of biologically active agents to specific tissues and cells. The composition comprises microparticles containing a biocompatible polymer, a water-soluble polymer and a biologically active agent. In one embodiment, the biologically active agent is an antigen or an immunomodulator. In another embodiment, the biologically is a labile agent. The microparticles have a number median diameter of greater than 20 microns upon administration. The water-soluble polymer is present in the sustained released composition in at least about 20% of the dry weight of the microparticle. the sustained release composition provides for the dissolution of the water-soluble polymer of the composition upon hydration, at a much greater rate than the degradation of the biocompatible polymer. This variance is solubility generates pseudo-microparticles which have a number median diameter which is substantially smaller than the size of the administered microparticles. The pseudo-microparticles can be engulfed by antigen presenting cells of the immune system, or absorbed by the Peyer's patches in the gut.
A technique is provided for managing medical consumption. The technique includes a micro controller unit (MCU), a transceiver communicatively coupled to an electronic device, plurality of compartments for storing a plurality of medicines, and a memory. The MCU automatically generates an indicia associated with each of the plurality of compartments. Each of the plurality of compartments is assigned unique generated indicia. Further, the indicia is transmitted to a pharmacy server along with medical prescription data. A label of each of the unique generated indicia is affixed to a packaging of each of a plurality of medicines as provided in the medical prescription. Each of the plurality of medicines is stored in corresponding plurality of compartments having the same unique generated indicia, and each compartment stores only one type of medicine from the plurality of medicines. A reminder alert is generated for indicating a time for consuming the plurality of medicines.
Chronic fistulas are a dreaded complication to surgery. They are often persistent to treatment and involve several negative side effects and a significant reduction in quality of life. We present a case report of a 36-year-old male with a deep chronic fistula in the pelvis after pouch surgery. More than 60 procedures were performed under general anaesthesia without treatment effect. Through a multidisciplinary approach a complete rectum extirpation and reconstruction with a free latissimus dorsi flap was performed. The patient was seen at followup 18 months after the surgery; pain free and without relapse.
PURPOSE:To enable obtaining of mycelia, composed of obligate Phellinus yucatensis Imaz. and having carcinostatic action by culturing strips prepared from fruit bodies of the Phellinus yucatensis Imaz. in a culture medium containing a dried and pulverized mulberry sapling as a chief ingredient and further glucose added thereto. CONSTITUTION:Strips prepared from fruit bodies of Phellinus yucatensis Imaz. naturally growing on an old tree of a mulberry are transferred to an agar culture medium and separately cultured. Hyphae thereof are then inoculated into a culture medium having a composition consisting essentially of a dried and pulverized mulberry sapling and containing glucose added thereto and cultured. Water in an amount of 2-3 times based on the wet weight of the resultant fruit bodies of the Phellinus yucatensis Imaz. is subsequently added thereto to carry out hot water extraction. The obtained extract is filtered through a gauze, concentrated under reduced pressure and then converted into extract powder of the Phellinus yucatansis Imaz. hyphae by using a means such as lyophilization. Thereby, obligate Phellinus yucatensis Imaz. growing on the old tree of the mulberry can be readily cultured to open the way for widely utilizing excellent anticancer effects of the Phellinus yucatansis Imaz.
BACKGROUND: Advances in blood biomarker discovery have enabled the improved diagnosis and prognosis of Alzheimer's disease (AD). Most branched-chain amino acids, except isoleucine (Ile), are correlated with both mild cognitive impairment (MCI) and AD. Therefore, this study investigated the association between serum Ile levels and MCI/AD.
METHODS: This study stratified 700 participants from the Alzheimer's Disease Neuroimaging Initiative database into four diagnostic groups: cognitively normal, stable MCI, progressive MCI, and AD. Analysis of covariance and chi-square analyses were used to test the demographic data. Receiver operating curve analyses were used to calculate the diagnostic accuracy of different biomarkers and were compared by MedCalc 20. Additionally, Cox proportional hazards models were used to measure the ability of serum Ile levels to predict disease conversion. Finally, a linear mixed-effects model was used to evaluate the associations between serum Ile levels and cognition, brain structure, and metabolism.
RESULTS: Serum Ile concentration was decreased in AD and demonstrated significant diagnostic efficacy. The combination of serum Ile and cerebrospinal fluid (CSF) phosphorylated tau (P-tau) improved the diagnostic accuracy in AD compared to total tau (T-tau) alone. Serum Ile levels significantly predicted the conversion from MCI to AD (cutoff value of 78.3 μM). Finally, the results of this study also revealed a correlation between serum Ile levels and the Alzheimer's Disease Assessment Scale cognitive subscale Q4.
CONCLUSIONS: Serum Ile may be a potential biomarker of AD. Ile had independent diagnostic efficacy and significantly improved the diagnostic accuracy of CSF P-tau in AD. MCI patients with a lower serum Ile level had a higher risk of progression to AD and a worse cognition assessment.
The primary purpose of this study is to determine whether, in patients with acute coronary syndromes not taking statins in chronic administration, high doses of a hydrophilic statin (rosuvastatin) administered before coronary angiography and/or angioplasty, may exert a renal-protective effect by reducing the incidence of contrast nephropathy. Contrast induced nephropathy is defined as increased values of creatinine \>= 0.3 mg/dl from baseline values, within 72 hours after contrast medium exposure.

Secondary end points: 1) verify if short-term (\<48 hours)statin administration reduces the peak levels and the curve areas of markers of myocardial necrosis throughout the hospitalization period and if reduces the occurrence of periprocedural infarction. Biochemical markers (quantitative creatine kinase-MB (CK-MB) mass and Troponin I) are measured at admission and at 6, 12, and 24 hours during the first day then once daily, immediately before angiography, and 24 hours thereafter. In patients who underwent coronary angioplasty (PCI), biochemical markers were measured at 12 and 24 hours after the procedure. Data were fitted, peak values and curve areas calculated; the occurrence of periprocedural infarction was defined as a CK-MB mass elevation more than three times the upper limit of normal within 24 hours after PCI. 2) determine the distribution of peripheral lymphocytic populations at the entry and at discharge using the flow cytometric analysis; 3) analyze the clinical composite outcome of death, myocardial infarction, urgent revascularization, dialysis and stroke at 30 days and 6 months.
The invention concerns a solid aqueous gel comprising: (i) at least a hydrophilic gelling agent and (ii) a powder phase comprising at least a filler with deformable particles, the gelling agent being present in the gel at a content not more than 20 wt. % relative to the gel total weight. The invention also concerns a solid composition, having a continuous aqueous phase, comprising said gel. Said gel can be used in stick or waterpact form and can constitute make-up products for the skin and/or mucous membranes and/or keratinous fibres. It has a hardness enabling both an easy disintegration of the product and good stick cohesion. Said gel or said composition can be directly applied on the skin or with a sponge and exhibit very good cosmetic qualities (comfort and softness).
The invention relates to a ruthenium complex, a ruthenium-RGD peptide conjugate, and a preparation method and application thereof. The conjugate is obtained by coupling and synthesizing a ruthenium complex (RuM) and an RGD peptide (RGDfK). Wherein the ruthenium complex RuM has the formula: [ Ru (dmp) 2 (X‑COOH)](PF 6 ) 2 Wherein the ligand represented by X is: 1, 2-dimethyl-1H-imidazole [4,5-f ]][1,10]Phenanthroline. RGD peptide is a commercial agent (RGDfK, shanghai megabiosis). The conjugate RuM-RGD is prepared from ruthenium complex RuM and RGD peptide RGDfK through condensation reaction. The RuM-RGD conjugate has strong inhibiting effect on glioma cells U87, can be accumulated in mitochondria of U87 tumor cells and inhibit tumor cell proliferation, and can be used as a novel antitumor drug taking the mitochondria of the tumor cells as a target.
This study aims to explore the mechanism of aqueous extract of Strychni Semen(SA) in relieving pain in the rat model of rheumatoid arthritis(RA) via Toll-like receptor 4(TLR4)/tumor necrosis factor-α(TNF-α)/matrix metalloproteinase-9(MMP-9) signaling pathway. Firstly, the main chemical components of Strychni Semen were searched against TCMSP, TCMID, ETCM, and related literature, and the main targets of the chemical components were retrieved from TargetNet and SwissTargetPrediction. The main targets of RA and pain were searched against GeneCards, Online Mendelian Inheritance in Man(OMIM), and Therapeutic Target Database(TTD). Venny 2.1.0 was used to obtain the common targets shared by Strychni Semen, RA, and pain, and STRING and Cytoscape 3.6.1 were used to build the protein-protein interaction network. Then, molecular docking was carried out in AutoDock Vina. Finally, the rat model of type Ⅱ collagen-induced arthritis(CIA) was established. The up-down method and acetone method were employed to examine the mechanical pain threshold and cold pain threshold of rats, and the pain-relieving effect of SA on CIA rats was evaluated comprehensively. Hematoxylin-eosin(HE) staining was employed to evaluate the histopathological changes of joints in CIA rats. The expression levels of key target proteins was determined by immunohistochemistry and Western blot, and the mRNA levels of key targets were determined by real-time fluorescence quantitative polymerase chain reaction(real-time PCR). The results of network prediction showed that Strychni Semen may act on the TLR4/TNF-α/MMP-9 signaling pathway to exert the pain-relieving effect. The results of molecular docking showed that brucine, the main active component of SA, had strong binding ability to TLR4, TNF-α, and MMP-9. The results of animal experiments showed that SA improved the mechanical and cold pain sensitivity(P<0.05, P<0.01) and reduced the joint histopathological score of CIA rats(P<0.01). In addition, medium and high doses of SA down-regulated the protein and mRNA levels of TNF-α, TLR4, and MMP-9(P<0.05,P<0.01). In conclusion, SA alleviated the mechanical pain sensitivity, cold pain sensitivity, and joint histopathological changes in CIA rats by inhibiting the over activation of TLR4/TNF-α/MMP-9 signaling pathway.
The utility model relates to an antitumor pill, and relates to an antineoplastic pill. The utility model comprises four layers, wherein the inner layer is made from the mixture of balsam pear powders and orange meals. The second layer is a sugar layer. The third layer is made from the mixture of grape powders, Chinese chive seed powders, glossy privet fruit powders, sanqi powders and atractyloside powders. The outer layer is a sugar sayer. The pill is a natural pill. The utility model is mainly provided with balsam pear powders and orange meals, has the advantages of innocuity, full asthenia and sthenia combination, cold and dampness moistening, and mutual generation and fight, can improve human body immunity, prevents healthy cells from cancerization, destroys cancer cell tunicae, makes cancer cell growth lose vigor, restrains cancer cells from diffusion, and makes cancer tissues disintegrated, melted and transmuted. The pill is proved to have certain curative effect on various cancerous protuberances of breast cancer, lung cancer, stomach cancer, rear-throat lethal granuloma, esophagus cancer, etc., through hospital clinical usage.
Our goal is to determine if an individual's level of inflammation determines their response to vaccination. The aging process and certain diseases, like type-2 diabetes, have been characterized as chronic inflammatory conditions. These individuals have higher rates of influenza disease and health care costs; hence, yearly vaccination is recommended. There is a paucity of information comparing vaccination in these high-risk groups and identifying biomarkers that can predict vaccine efficacy. The investigators hypothesize that elderly and diabetic patients have reduced responses to seasonal influenza vaccination that are inversely proportional to their level of chronic inflammation. In this pilot proposal, the investigators will examine adult and elderly diabetic and non-diabetic adults for markers of inflammation and vaccine efficacy before and after influenza vaccination. These studies will help our understanding of how chronic inflammatory diseases impact immunologic function and future research on mitigation strategies.
Detergent compositions comprise at least one purified polyethylene glycol alkylthioether, RS(CH2.CH2.O)nH, wherein R is C2- 18 alkyl, and n is an integer which may vary from 1 to 14, together with a carrier or diluent, the purified polyethylene glycol alkylthioether having not more than 0.5 part per 1000 of iron. The compositions may be in the form of creams or lotions.ALSO:A tert.-dodecyl mercaptan-ethylene oxide condensate, C12H25S(CH2.CH2.O)12H, is prepared by reacting 12 mols. of ethylene oxide with 1 mol. of tert.-dodecyl mercaptan at 140-160 DEG  C. in the presence of aq. Na2CO3 as catalyst. The Specification refers generally to compounds of the formula RS(CH2CH2O)nH where R is an alkyl radical, preferably branched, of 2 to 18 carbon atoms, and n is up to 14, for use in medicaments.  They may be purified by distillation, or treatment with wood charcoal or infusorial earth.ALSO:A medicament for the treatment of acne, seborrhea and seborrheic dermatitis comprises at least one purified polyethylene glycol alkylthioether of the formula R-S(CH2.CH2O)nH in which R is a C2-18 alkyl radical and n is an integer which may vary from 1 to 14 and a carrier or diluent, the purified polyethylene glycol alkyl thioether having not more than 0.5 part per 1000 of iron.  The medicament may be in the form of a cream or lotion.
PURPOSE:To obtain a solid preparation for oral administration, having excellent slowly releasing effect without necessitating complicated preparation steps, by adding a phospholipid to a drug. CONSTITUTION:A drug component excluding eicosapolyenoic acid compound and prostaglandin compound (e.g. indomethacin, diclofenac, etc.) is mixed with 30-99.99%(w/w) phospholipid based on the whole solid preparation and the mixture is thoroughly kneaded with a proper amount of a solvent such as water, ethanol, etc. The kneaded product is sieved to uniformize the grain size and tabletted to obtain the objective solid preparation. The phospholipid is e.g. phosphatidylcholine, natural animal or vegetable lecithin and preferably hydrogenated phospholipid. The obtained preparation is optionally subjected to enteric coating to obtain a slowly releasing enteric drug.
This is a randomized (study drug assigned by chance), open-label (all people involved know the identity of the intervention) study to evaluate the clinical use, safety and ease of care of two patient-controlled analgesia (PCA) systems to deliver pain medication either through the skin or intravenously. The fentanyl hydrochloride PCA system, which delivers the medication through the skin, and morphine intravenous (IV)- PCA, which requires injection into a vein, are used for management of moderate to severe acute pain in postoperative patients who have undergone elective major abdominal or orthopedic surgery. These patients, who are expected to require postoperative pain relief with strong opioids for at least 24 hours, will control the delivery of medication for up to 3 days. Assessment of effectiveness include: patient's global assessment of pain control (poor, fair, good, excellent); Pain Intensity, measured on a visual numerical rating scale from 0 to 10, where 0 means no pain and 10 means the worst possible pain; Ease-of-Care questionnaires including Patient Ease-of-Care questionnaire, Nurse Ease-of-Care questionnaire, and Physical Therapist Ease-of-Care questionnaire; and, total number of doses delivered by patients in the fentanyl transdermal PCA or morphine IV PCA treatment groups. Safety evaluations include vital signs (pulse, blood pressure) and oxygen saturation, respiratory function, and the incidence of adverse events. The study hypothesis is that fentanyl transdermal PCA is not inferior to morphine IV PCA treatment in patient's global assessment of method of pain control during the first 24 hours after surgery. Transdermal PCA: 40 micrograms fentanyl per on-demand dose, each delivered over 10 minutes for a maximum of 6 doses/hr for 24 hours (maximum of 80 doses, 3.2milligrams). Morphine IV PCA: morphine doses with a maximum of 20 milligrams per 2 hours for 24 hours (maximum 12 doses, 240 milligrams).